Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review.

IF 0.7 Q4 OPHTHALMOLOGY

Case Reports in Ophthalmological Medicine Pub Date : 2021-01-22 eCollection Date: 2021-01-01 DOI:10.1155/2021/6616021

Mónica Gimeno-Carrero, María-Jesús Suárez-Fernández, Beatriz Alonso-Martín, Almudena de-Pablo-Cabrera, María-Concepción Garrido-Ruíz, Enrique Mencía-Gutiérrez

{"title":"Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review.","authors":"Mónica Gimeno-Carrero, María-Jesús Suárez-Fernández, Beatriz Alonso-Martín, Almudena de-Pablo-Cabrera, María-Concepción Garrido-Ruíz, Enrique Mencía-Gutiérrez","doi":"10.1155/2021/6616021","DOIUrl":null,"url":null,"abstract":"<p><p>Conjunctival neoplasia is one of the most frequent tumors in the eye. Actinic keratosis (AK) or solar keratosis is a precancerous lesion that is included with other epithelial tumors. This alteration does not break the basal membrane. There is enough evidence of successful outcomes to consider interferon alfa-2b (IFN alfa-2b) as the first choice of treatment for this type of tumors. In addition, side effects are mild and uncommon. We report a case in an 83-year-old woman who was referred to evaluate a leukoplakia in the tarsal conjunctiva of the lower left eyelid that measured 1 cm in diameter. Pathological study revealed AK. After the INF alfa-2b treatment, we observed conjunctival hyperemia, noninfiltrated upper nasal de-epithelization, and inferior nasal bulla. AK with presentation in conjunctiva is rarely described and in tarsal conjunctiva is exceptional. It is the first case published with only tarsal conjunctiva affectation.</p>","PeriodicalId":9603,"journal":{"name":"Case Reports in Ophthalmological Medicine","volume":" ","pages":"6616021"},"PeriodicalIF":0.7000,"publicationDate":"2021-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847316/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/6616021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Conjunctival neoplasia is one of the most frequent tumors in the eye. Actinic keratosis (AK) or solar keratosis is a precancerous lesion that is included with other epithelial tumors. This alteration does not break the basal membrane. There is enough evidence of successful outcomes to consider interferon alfa-2b (IFN alfa-2b) as the first choice of treatment for this type of tumors. In addition, side effects are mild and uncommon. We report a case in an 83-year-old woman who was referred to evaluate a leukoplakia in the tarsal conjunctiva of the lower left eyelid that measured 1 cm in diameter. Pathological study revealed AK. After the INF alfa-2b treatment, we observed conjunctival hyperemia, noninfiltrated upper nasal de-epithelization, and inferior nasal bulla. AK with presentation in conjunctiva is rarely described and in tarsal conjunctiva is exceptional. It is the first case published with only tarsal conjunctiva affectation.

Abstract Image

查看原文本刊更多论文

干扰素α -2b治疗结膜角膜光化性角化病1例报告及文献复习。

结膜瘤是眼部最常见的肿瘤之一。光化性角化病(AK)或日光性角化病是一种癌前病变，包括与其他上皮性肿瘤。这种改变不会破坏基膜。有足够的证据表明成功的结果考虑干扰素α -2b (IFN α -2b)作为治疗这类肿瘤的首选。此外，副作用轻微，不常见。我们报告了一例83岁的妇女，她被转介去评估左下眼睑结膜的白斑，直径为1厘米。病理检查显示AK。经INF -2b治疗后，我们观察到结膜充血，非浸润性上鼻上皮脱落和下鼻大疱。结膜AK的表现是罕见的，在跗骨结膜是例外。这是第一例仅跗骨结膜畸形的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Ophthalmological Medicine OPHTHALMOLOGY-

自引率

0.00%

发文量

审稿时长

14 weeks